| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |